Crown Bioscience, Inc. (Taicang)

Jie Cai

Henry Qixiang Li

Yiyou Chen

Sheng Guo

Daiwei Chen

Juan Zhang

Henry Li

Jie Yang

Gene expression signature predictive of cancer patient response to multi-kinase inhibitor is disclosed. Also disclosed are methods predicting the efficacy of the multi-kinase inhibitor for treating cancer in a patient. Also disclosed are methods for distinguishing responders from non-responders to a multi-kinase inhibitor in treating cancer. Also disclosed are methods for treating a cancer patient with a multi-kinase inhibitor.

Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same

The present disclosure provides methods of detecting a fusion gene of HNF4G and RSPO2 in a nucleic acid-containing sample, and a primer set, a probe set and a kit for detecting the fusion gene are also provided. Animal models for a human disease positive for the fusion gene are also provided herein. In addition, the present disclosure relates to the methods for assessing and identifying an agent effective on the fusion gene of HNF4G and RSPO2 or a human disease positive for a fusion gene of HNF4G and RSPO2 and thereby treating said disease are also provided.

HNF4G-RSPO2 fusion gene and use thereof in treatment of cancer

The present invention relates to methods for treating gastric neoplasias, in particular treating patients who have been previously determined to have an EGFR biomarker. Gastric carcinoma (GC) is one of the most common and deadest cancers with &#x2212;1 million diagnoses and &#x2212;0.7 million deaths each year worldwide, with high incidence in Eastern Asia.

Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents

Growing community of inventors

Taicang, China

Jie Cai